Results 21 to 30 of about 110,851 (248)
GSK-3 and mitochondria in cancer cells [PDF]
Frontiers in Oncology, 2013 GSK-3 is a multifunctional kinase that is located in the cytosol, nucleus, and mitochondria of all cell types, and it is involved in the pathogenesis of a variety of diseases. In cancer, GSK-3 modulates the response of the cell death machinery to stress stimuli, including chemotherapeutics.
CHIARA, FEDERICA, RASOLA, ANDREA
openaire +4 more sources
Polarized regulation of glycogen synthase kinase-3β is important for glioma cell invasion. [PDF]
PLoS ONE, 2013 Glioma malignancy greatly depends on its aggressive invasion. The establishment of cell polarity is an important initial step for cell migration, which is essential for cell-directional translocation.
Qifei Zou +3 more
doaj +1 more source
Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
BMC Cancer, 2018 Background Neuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB will have relapse and therefore long-term event free survival is very minimal.
Selvi Kunnimalaiyaan +4 more
doaj +1 more source
Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection
iScience, 2021 Summary: Glycogen synthase kinase-3 (GSK-3) is a positive regulator of PD-1 expression in CD8+ T cells and GSK-3 inhibition enhances T cell function and is effective in the control of tumor growth.
Lynette Steele +6 more
doaj +1 more source
Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity [PDF]
The International Journal of Neuropsychopharmacology, 2003 Glycogen synthase kinase (GSK)-3 protein levels and GSK-3 activity were previously found to be over 40% reduced in the post-mortem prefrontal cortex of schizophrenic patients. Lithium and valproate have been reported to selectively inhibit GSK-3. We hypothesized that in-vivo administration of lithium and valproate would result in up-regulation of GSK-3
Nitsan, Kozlovsky +3 more
openaire +2 more sources
GSK-3 inhibitors for Alzheimer’s disease
Expert Review of Neurotherapeutics, 2007 Glycogen synthase kinase (GSK)-3 has been proposed as the link between the two histopathological hallmarks of Alzheimer's disease, the extracellular senile plaques made of beta-amyloid and the intracellular neurofibrillary tangles made of hyperphosphorylated tau.
Ávila, Jesús, Hernández, Félix
openaire +3 more sources
Image Analysis and Stereology, 2020 Glycogen synthase kinase 3 (GSK-3) plays an important role in metabolic regulation in skeletal muscles, and both insulin and adrenaline stimulate GSK-3 phosphorylation. The aim of the present study was to study the effect of insulin and adrenaline on GSK-
Katja Fink +5 more
doaj +1 more source
GSK-3: a multifaceted player in acute leukemias
Leukemia, 2021 Glycogen synthase kinase 3 (GSK-3) consists of two isoforms (α and β) that were originally linked to glucose metabolism regulation. However, GSK-3 is also involved in several signaling pathways controlling many different key functions in healthy cells.
A. M. Martelli +4 more
openaire +5 more sources
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation.
The Journal of biological chemistry, 2007 Peer ...
Goñi-Oliver, Paloma +3 more
openaire +3 more sources
Cells, 2021 Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link between ...
Stephen L. Abrams +16 more
doaj +1 more source